Safety Tolerability and Efficacy Study of Cabaletta to Treat Oculopharyngeal Muscular Dystrophy (OPMD) Patients — HOPEMD

Oculopharyngeal Muscular Dystrophy Clinical Trial

Official title:
Multi-Center, Dose-Escalation Study, to Assess Safety, Tolerability and Efficacy of Intravenous Cabaletta® in OPMD Patients

Status Completed

Clinical Trial Summary

The Purpose of this study is to assess the Safety, Tolerability and Efficacy of Intravenous Cabaletta® in Oculopharyngeal Muscular Dystrophy (OPMD) Patients.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Muscular Dystrophies
Muscular Dystrophy, Oculopharyngeal
Oculopharyngeal Muscular Dystrophy

Clinical Trial Details

NCT number	NCT02015481
Study type	Interventional
Source	Bioblast Pharma Ltd.
Contact
Status	Completed
Phase	Phase 2
Start date	February 2014
Completion date	April 2016

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02877784` - Screening in Oculopharyngeal Muscular Dystrophy
Recruiting	`NCT06185673` - A Study to Evaluate the Safety and Clinical Activity of Intramuscular Doses of BB-301 Administered to Subjects With Oculopharyngeal Muscular Dystrophy With Dysphagia	Phase 1/Phase 2
Enrolling by invitation	`NCT04009408` - Expiratory Muscle Strength Training (EMST) in Neuromuscular Disorders	N/A
Recruiting	`NCT03874910` - Pathology Analysis of OPMD Patient Myotomies
Withdrawn	`NCT04226924` - Treatment of Oculopharyngeal Muscular Dystrophy With Trehalose	Phase 2
Recruiting	`NCT02158156` - Effect of Aerobic Training in Patients With Oculopharyngeal Muscular Dystrophy	N/A
Withdrawn	`NCT03161847` - Natural History Study of Oculopharyngeal Muscular Dystrophy